Tenax Therapeutics (TENX) Liabilities and Shareholders Equity (2011 - 2026)
Tenax Therapeutics recorded quarterly Liabilities and Shareholders Equity of $123.2 million in Q1 2026, up 18.18% quarter-over-quarter from $104.2 million in Q4 2025, and up 9.92% year-over-year from $112.1 million in Q1 2025.
Tenax Therapeutics' Liabilities and Shareholders Equity history runs 15 years deep, the most recent figure standing at $123.2 million for Q1 2026.
- In Q1 2026, Liabilities and Shareholders Equity rose 9.92% year-over-year to $123.2 million; the TTM figure through Mar 2026 stood at $436.1 million (up 36.64% YoY), while the FY2025 annual figure was $104.2 million, up 7.8% from the prior year.
- Liabilities and Shareholders Equity came in at $123.2 million for Q1 2026 at Tenax Therapeutics, up from $104.2 million in the prior quarter.
- In the past five years, Liabilities and Shareholders Equity ranged from a high of $123.2 million in Q1 2026 to a low of $3.4 million in Q4 2022.
- A 5-year average of $49.6 million and a median of $14.5 million in 2024 frame the typical range for Liabilities and Shareholders Equity.
- Across the five-year window, Liabilities and Shareholders Equity sank 46.82% in 2022 and surged 897.06% in 2025, its largest moves.
- Tenax Therapeutics' Liabilities and Shareholders Equity stood at $3.4 million in 2022, then surged by 243.2% to $11.7 million in 2023, then jumped by 727.44% to $96.7 million in 2024, then advanced by 7.8% to $104.2 million in 2025, then gained by 18.18% to $123.2 million in 2026.
- According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $123.2 million, $104.2 million, and $102.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 14.93 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 37.37 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 1.73 Bn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 78.88 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 33.89 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 26.48 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 23.64 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 40.87 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 5.13 Bn |
| 10 | Tenax Therapeutics | 542.72 Mn | 542.72 Mn | - | 123.18 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 123.18 Mn |
| Dec 31, 2025 | 104.23 Mn |
| Sep 30, 2025 | 102.81 Mn |
| Jun 30, 2025 | 105.86 Mn |
| Mar 31, 2025 | 112.06 Mn |
| Dec 31, 2024 | 96.69 Mn |
| Sep 30, 2024 | 99.78 Mn |
| Jun 30, 2024 | 10.62 Mn |
| Mar 31, 2024 | 14.46 Mn |
| Dec 31, 2023 | 11.69 Mn |
| Sep 30, 2023 | 11.89 Mn |
| Jun 30, 2023 | 14.05 Mn |
| Mar 31, 2023 | 15.27 Mn |
| Dec 31, 2022 | 3.40 Mn |
| Sep 30, 2022 | 4.74 Mn |
| Jun 30, 2022 | 8.36 Mn |
| Mar 31, 2022 | 3.74 Mn |
| Dec 31, 2021 | 5.99 Mn |
| Sep 30, 2021 | 8.91 Mn |
| Jun 30, 2021 | 2.89 Mn |
| Mar 31, 2021 | 4.56 Mn |
| Dec 31, 2020 | 6.87 Mn |
| Sep 30, 2020 | 9.00 Mn |
| Jun 30, 2020 | 5.35 Mn |
| Mar 31, 2020 | 5.95 Mn |
| Dec 31, 2019 | 6.37 Mn |
| Sep 30, 2019 | 7.77 Mn |
| Jun 30, 2019 | 9.66 Mn |
| Mar 31, 2019 | 11.46 Mn |
| Dec 31, 2018 | 13.34 Mn |
| Sep 30, 2018 | 5.45 Mn |
| Jun 30, 2018 | 7.03 Mn |
| Mar 31, 2018 | 8.31 Mn |
| Dec 31, 2017 | 9.89 Mn |
| Sep 30, 2017 | 11.00 Mn |
| Jun 30, 2017 | 13.45 Mn |
| Mar 31, 2017 | 19.15 Mn |
| Dec 31, 2016 | 23.34 Mn |
| Sep 30, 2016 | 59.71 Mn |
| Jun 30, 2016 | 64.13 Mn |
| Dec 31, 2015 | 72.99 Mn |
| Apr 30, 2013 | 3.18 Mn |
| Jan 31, 2013 | 3.04 Mn |
| Oct 31, 2012 | 3.54 Mn |
| Jul 31, 2012 | 5.13 Mn |
| Apr 30, 2012 | 4.14 Mn |
| Jan 31, 2012 | 5.89 Mn |
| Oct 31, 2011 | 4.55 Mn |
| Jul 31, 2011 | 6.18 Mn |
| Apr 30, 2011 | 2.92 Mn |